Review: taking Novantrone and Copaxone together


Summary

Drug interactions are reported among people who take Novantrone and Copaxone together. This review analyzes the effectiveness and drug interactions between Novantrone and Copaxone. It is created by eHealthMe based on reports of 155 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Novantrone and Copaxone >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Novantrone

Novantrone has active ingredients of mitoxantrone hydrochloride. It is often used in multiple sclerosis. (latest outcomes from Novantrone 3,057 users)

Copaxone

Copaxone has active ingredients of glatiramer acetate. It is often used in multiple sclerosis. (latest outcomes from Copaxone 14,035 users)

On Aug, 30, 2016

155 people who take Novantrone, Copaxone are studied.


Number of reports submitted per year:

Novantrone and Copaxone drug interactions.

Drug effectiveness over time:

Novantrone:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Copaxone:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 100.0% - (1 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Novantrone:
  • female: 100.0% - (1 of 1 people)
  • male: 0.0% - (0 of 0 people)
Copaxone:
  • female: 100.0% - (1 of 1 people)
  • male: 0.0% - (0 of 0 people)

Drug effectiveness by age:

Novantrone:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 100.0% - (1 of 1 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)
Copaxone:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 100.0% - (1 of 1 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

< 1 month:
  • cardiac disorder
  • hyperhidrosis
  • myalgia
  • paralysis
  • skin reaction
  • atrial fibrillation
  • atrial pressure increased
  • cardiac failure congestive
  • cardiomyopathy
  • chest pain
1 - 6 months:
  • hypovolaemic shock
  • myocardial infarction
  • renal insufficiency
  • respiratory failure
  • septic shock
  • stevens johnson syndrome
  • acute promyelocytic leukaemia
  • breast cancer female
  • cardiac failure
  • cellulitis gangrenous
6 - 12 months:
  • staphylococcal infection
  • headache
  • asthma
  • bladder disorder
  • upper respiratory tract infection
  • accident
  • oesophageal carcinoma
  • road traffic accident
  • metastases to liver
  • catheter related infection
1 - 2 years:
  • acute promyelocytic leukaemia
  • nausea
  • cerebrovascular accident
  • cholecystitis
  • deep vein thrombosis
  • haematuria
  • oesophageal carcinoma
  • acute myeloid leukaemia
  • cardiac failure
  • disseminated intravascular coagulation
2 - 5 years:
  • acute promyelocytic leukaemia
  • amenorrhoea
  • liposarcoma
  • metastases to liver
  • premature menopause
  • red blood cell count decreased
  • small intestine carcinoma metastatic
  • acute myeloid leukaemia
  • affect lability
  • anaemia
5 - 10 years:
  • breast cancer
  • liposarcoma
  • acute promyelocytic leukaemia
  • apparent life threatening event
  • arthralgia
  • cerebrovascular accident
  • chest pain
  • cholecystitis
  • circulatory collapse
  • deep vein thrombosis
not specified:
  • multiple sclerosis relapse
  • nausea
  • acute myeloid leukaemia
  • staphylococcal infection
  • fatigue
  • myocardial infarction
  • pneumonia
  • multiple sclerosis
  • syncope
  • acute promyelocytic leukaemia

Most common drug interactions by gender *:

female:
  • staphylococcal infection
  • headache
  • asthma
  • bladder disorder
  • upper respiratory tract infection
  • accident
  • multiple sclerosis relapse
  • nausea
  • acute myeloid leukaemia
  • cardiac failure
male:
  • acute promyelocytic leukaemia
  • oesophageal carcinoma
  • metastases to liver
  • myocardial infarction
  • cerebrovascular accident
  • metastases to bone
  • nausea
  • pneumonia
  • cholecystitis
  • convulsion

Most common drug interactions by age *:

20-29:
  • b precursor type acute leukaemia
  • back pain
  • bronchopulmonary aspergillosis
  • cerebrovascular accident
  • cough
  • cystitis
  • decubitus ulcer
  • disease progression
  • diverticulitis
  • haematoma
30-39:
  • staphylococcal infection
  • headache
  • asthma
  • bladder disorder
  • upper respiratory tract infection
  • accident
  • multiple sclerosis relapse
  • nausea
  • road traffic accident
  • amenorrhoea
40-49:
  • myocardial infarction
  • ejection fraction decreased
  • nausea
  • acute promyelocytic leukaemia
  • cerebrovascular accident
  • cholecystitis
  • deep vein thrombosis
  • convulsion
  • fatigue
  • haematemesis
50-59:
  • oesophageal carcinoma
  • metastases to liver
  • nausea
  • acute promyelocytic leukaemia
  • alopecia
  • haematuria
  • metastases to bone
  • multiple sclerosis
  • acute myeloid leukaemia
  • chest pain
60+:
  • cardiac failure
  • pneumonia
  • multiple sclerosis relapse
  • colon cancer
  • constipation
  • helicobacter infection
  • infection susceptibility increased
  • left ventricular dysfunction
  • malaise
  • pancreatic carcinoma

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Novantrone and Copaxone?

Can you answer these questions?

More questions for: Novantrone, Copaxone

You may be interested in these reviews

More reviews for: Novantrone, Copaxone

On eHealthMe, Novantrone (mitoxantrone hydrochloride) is often used to treat multiple sclerosis. Copaxone (glatiramer acetate) is often used to treat multiple sclerosis. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.